Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 110 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,526,779 | +80.8% | 126,389 | +143.4% | 0.00% | +200.0% |
| Q1 2024 | $844,496 | +89.9% | 51,937 | -43.0% | 0.00% | -50.0% |
| Q4 2022 | $444,778 | -29.1% | 91,143 | +391.2% | 0.00% | 0.0% |
| Q2 2021 | $627,000 | -43.8% | 18,554 | -49.7% | 0.00% | -71.4% |
| Q1 2021 | $1,116,000 | +14.3% | 36,889 | +87.1% | 0.01% | 0.0% |
| Q4 2020 | $976,000 | +63.8% | 19,715 | +26.9% | 0.01% | -12.5% |
| Q3 2020 | $596,000 | -15.0% | 15,535 | -4.3% | 0.01% | -27.3% |
| Q2 2020 | $701,000 | -29.2% | 16,231 | -57.2% | 0.01% | -56.0% |
| Q1 2020 | $990,000 | -56.3% | 37,950 | -47.6% | 0.02% | +92.3% |
| Q4 2019 | $2,265,000 | +76.3% | 72,488 | +47.0% | 0.01% | +18.2% |
| Q3 2019 | $1,285,000 | +184.9% | 49,314 | +150.3% | 0.01% | +175.0% |
| Q2 2019 | $451,000 | – | 19,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,757,000 | 9.37% |
| Sofinnova Investments, Inc. | 2,194,278 | $31,641,000 | 1.84% |
| MPM BioImpact LLC | 443,702 | $6,398,000 | 1.52% |
| Artal Group S.A. | 400,000 | $5,768,000 | 0.25% |
| Polar Capital Holdings Plc | 2,531,546 | $36,505,000 | 0.23% |
| ASHFORD CAPITAL MANAGEMENT INC | 101,970 | $1,470,000 | 0.22% |
| Lombard Odier Asset Management (Switzerland) SA | 168,795 | $2,434,000 | 0.21% |
| Soleus Capital Management, L.P. | 87,182 | $1,257,000 | 0.17% |
| Cormorant Asset Management, LP | 150,000 | $2,163,000 | 0.15% |
| Walleye Capital LLC | 437,344 | $6,307,000 | 0.12% |